ENDRA Life Sciences (NDRA) Liabilities and Shareholders Equity (2016 - 2026)

ENDRA Life Sciences (NDRA) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $3.4 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $3.4 million, up 8.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.1 million (down 54.38% YoY), and the FY2025 annual result was $3.9 million, down 13.44% from the prior year.
• Liabilities and Shareholders Equity slipped to $3.4 million in Q1 2026 per NDRA's latest filing, from $3.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $15.3 million in Q2 2022 and troughed at $2.0 million in Q3 2025.
• A 5-year average of $7.2 million and a median of $6.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2024 and 2025: Liabilities and Shareholders Equity climbed 12.96% in 2024, then slumped 76.56% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $9.3 million in 2022, then decreased by 27.17% to $6.8 million in 2023, then tumbled by 34.08% to $4.5 million in 2024, then declined by 13.44% to $3.9 million in 2025, then dropped by 10.78% to $3.4 million in 2026.
• Business Quant data shows NDRA's Liabilities and Shareholders Equity at $3.4 million in Q1 2026, $3.9 million in Q4 2025, and $2.0 million in Q3 2025.